<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823562</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-12125</org_study_id>
    <secondary_id>NCI-2013-00326</secondary_id>
    <nct_id>NCT01823562</nct_id>
  </id_info>
  <brief_title>Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery</brief_title>
  <official_title>Dietary Fruit Bioactives and Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/Ib trial is studying the absorption and metabolism of phytochemicals found in&#xD;
      black raspberries in men undergoing surgery for prostate cancer. This knowledge will help us&#xD;
      design future chemoprevention studies and assist in making future dietary recommendations for&#xD;
      men at high risk for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To conduct a dose-escalation study to determine safety and compliance of varying&#xD;
      lyophilized black raspberry (LBR) delivery vehicles (a gummy confection and a nectar) at two&#xD;
      different doses.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To precisely quantify changes in the content and distribution of black raspberry&#xD;
      phytochemicals and their metabolites in the blood and urine and correlate these&#xD;
      concentrations with prostate tissue phytochemicals.&#xD;
&#xD;
      II. Measure the ability of black raspberry gummy confection and nectar in altering hormonal&#xD;
      patterns (lower insulin-like growth factor-1 [IGF-I], higher insulin-like growth&#xD;
      factor-binding protein 3 [IGF-BP3], lower androgens) consistent with reduced prostate&#xD;
      carcinogenesis and in parallel with an enhanced capacity to quench reactive oxygen.&#xD;
&#xD;
      III. Investigate histopathologic, immunologic, and molecular biomarkers associated with&#xD;
      prostate carcinogenesis that may serve as surrogate endpoint biomarkers and provide&#xD;
      information regarding their ability to be modulated by black raspberries.&#xD;
&#xD;
      IV. Determine if consumption of black raspberries alters molecular markers in the human&#xD;
      prostate including: (a) neuroendocrine markers such as IGF-I and IGF-BP3, (b) signal&#xD;
      transduction markers such as phosphatase and tensin homologue (PTEN) and phospho-AKT, and (c)&#xD;
      angiogenesis regulators such as (vascular epithelial growth factor (VEGF).&#xD;
&#xD;
      V. Collect and store plasma and peripheral blood mononuclear cells (PBMCs) from each patient&#xD;
      to assess systemic markers of inflammation and immune response.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of lyophilized black raspberry gummy confection and&#xD;
      nectar. Patients are assigned to 1 of 7 treatment arms.&#xD;
&#xD;
      ARM I: Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.&#xD;
&#xD;
      ARM II: Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.&#xD;
&#xD;
      ARM III: Patients follow a low ellagitannin diet for 4-6 weeks and then undergo&#xD;
      prostatectomy.&#xD;
&#xD;
      ARM IV: Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy&#xD;
      orally (PO) daily for 4-6 weeks and then undergo prostatectomy.&#xD;
&#xD;
      ARM V: Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy&#xD;
      PO daily for 4-6 weeks and then undergo prostatectomy.&#xD;
&#xD;
      ARM VI: Patients follow a low ellagitannin diet and receive lower-dose black raspberry nectar&#xD;
      PO daily for 4-6 weeks and then undergo prostatectomy.&#xD;
&#xD;
      ARM VII: Patients follow a low ellagitannin diet and receive higher-dose black raspberry&#xD;
      nectar PO daily for 4-6 weeks and then undergo prostatectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2012</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">August 1, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance determined by consumption of at least 80% of black raspberries (BRB) and positive tests for urinary berry metabolites</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>A cohort will be considered compliant if the group mean consumption of the intervention product is at least 80%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of black raspberry metabolites in the urine collected 24 hours before surgery</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Analyzed on the log scale using a repeated measures linear model to judge the effect of treatment group in terms of fold-differences from baseline while controlling for body mass index (BMI) and age. Confidence intervals for dichotomous variables will be made using exact methods and confidence intervals for rank correlations between quantitative variables will be made using Fisher's transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PSA or PSA doubling time</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Analyzed on the log scale using a repeated measures linear model to judge the effect of treatment group in terms of fold-differences from baseline while controlling for BMI and age. Confidence intervals for dichotomous variables will be made using exact methods and confidence intervals for rank correlations between quantitative variables will be made using Fisher's transformation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Black Raspberry metabolites levels in the prostate tissue removed at surgery</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Confidence intervals for dichotomous variables will be made using exact methods and confidence intervals for rank correlations between quantitative variables will be made using Fisher's transformation.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (regular diet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (low polyphenol diet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (low ellagitannin diet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (lower-dose lyophilized black raspberry gummy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V (higher-dose black raspberry gummy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI (lower-dose black raspberry confection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VII (higher-dose black raspberry confection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lyophilized black raspberry confection</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm IV (lower-dose lyophilized black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm V (higher-dose black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm VI (lower-dose black raspberry confection)</arm_group_label>
    <arm_group_label>Arm VII (higher-dose black raspberry confection)</arm_group_label>
    <other_name>LBR confection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (regular diet)</arm_group_label>
    <arm_group_label>Arm II (low polyphenol diet)</arm_group_label>
    <arm_group_label>Arm III (low ellagitannin diet)</arm_group_label>
    <arm_group_label>Arm IV (lower-dose lyophilized black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm V (higher-dose black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm VI (lower-dose black raspberry confection)</arm_group_label>
    <arm_group_label>Arm VII (higher-dose black raspberry confection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>Follow a low polyphenol diet</description>
    <arm_group_label>Arm II (low polyphenol diet)</arm_group_label>
    <other_name>Dietary Modification</other_name>
    <other_name>intervention, dietary</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>Follow a low ellagitannin diet</description>
    <arm_group_label>Arm III (low ellagitannin diet)</arm_group_label>
    <arm_group_label>Arm IV (lower-dose lyophilized black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm V (higher-dose black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm VI (lower-dose black raspberry confection)</arm_group_label>
    <arm_group_label>Arm VII (higher-dose black raspberry confection)</arm_group_label>
    <other_name>Dietary Modification</other_name>
    <other_name>intervention, dietary</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (regular diet)</arm_group_label>
    <arm_group_label>Arm II (low polyphenol diet)</arm_group_label>
    <arm_group_label>Arm III (low ellagitannin diet)</arm_group_label>
    <arm_group_label>Arm IV (lower-dose lyophilized black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm V (higher-dose black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm VI (lower-dose black raspberry confection)</arm_group_label>
    <arm_group_label>Arm VII (higher-dose black raspberry confection)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (regular diet)</arm_group_label>
    <arm_group_label>Arm II (low polyphenol diet)</arm_group_label>
    <arm_group_label>Arm III (low ellagitannin diet)</arm_group_label>
    <arm_group_label>Arm IV (lower-dose lyophilized black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm V (higher-dose black raspberry gummy)</arm_group_label>
    <arm_group_label>Arm VI (lower-dose black raspberry confection)</arm_group_label>
    <arm_group_label>Arm VII (higher-dose black raspberry confection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have biopsy proven carcinoma of the prostate&#xD;
&#xD;
          -  Have chosen a radical prostatectomy for treatment of their disease after the medical&#xD;
             team has presented all possible treatment options&#xD;
&#xD;
          -  Not be receiving neoadjuvant hormonal or chemotherapy (other clinical trials)&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Not currently taking berry dietary supplements, or &quot;alternative&quot; products (Acai berry,&#xD;
             pomegranate, black raspberry, Optiberry, Juice Plus)&#xD;
&#xD;
          -  Have BUN/Cr (blood urea nitrogen and serum creatinine) within normal limits&#xD;
&#xD;
          -  Have liver enzymes within normal limits&#xD;
&#xD;
          -  Have complete blood count (CBC) within normal limits&#xD;
&#xD;
          -  Have prothrombin time/partial thromboplastin time (PT/PTT/INR) within normal limits&#xD;
&#xD;
          -  Voluntarily agree to participate and sign an informed consent document&#xD;
&#xD;
          -  Agree to have prostate biopsy blocks provided to the study for evaluation&#xD;
&#xD;
          -  Agree to consume a standardized vitamin and mineral supplement and avoid other&#xD;
             nutrition, dietary, or alternative medications/supplements for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Agree to follow a controlled polyphenolic and/ or ellagitannin diet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have an active malignancy other than prostate cancer that requires therapy&#xD;
&#xD;
          -  Have a prostate biopsy with less than 5% cancer involvement&#xD;
&#xD;
          -  Have a history of traumatic or surgical castration&#xD;
&#xD;
          -  Have a history of pituitary hormone diseases that currently require supplemental&#xD;
             hormonal administration (thyroid hormones, adrenocorticotropic hormone [ACTH], growth&#xD;
             hormone) or other endocrine disorders requiring hormone administration with the&#xD;
             exception of diabetes and osteoporosis&#xD;
&#xD;
          -  Are taking certain medications; no concurrent finasteride (Proscar) or other hormonal&#xD;
             agents for chemoprevention/treatment of benign prostate hyperplasia (BPH); utilizing&#xD;
             prescription medications for urinary outlet obstructive symptoms will not be&#xD;
             permitted; the use of non-prescription substances to improve urinary tract symptoms&#xD;
             will not be permitted (i.e. Saw Palmetto, other herbal, alternative products)&#xD;
&#xD;
          -  Have a known allergy to black raspberries, corn, and wheat products or those who have&#xD;
             never consumed any of these products&#xD;
&#xD;
          -  Have active metabolic or digestive illnesses such as malabsorptive disorders (Crohn's,&#xD;
             Celiac disease, irritable bowel syndrome [IBS]), renal insufficiency, hepatic&#xD;
             insufficiency, cachexia, or short bowel syndrome&#xD;
&#xD;
          -  Have significant loss of gastrointestinal organs due to surgery, except for appendix&#xD;
&#xD;
          -  Have altered immunity such as autoimmune disorders, cancer, anemia, hemophilia, and&#xD;
             blood dyscrasias&#xD;
&#xD;
          -  Have noticeable open lesions in the oral cavity, sores that have not healed for more&#xD;
             than 2 months or have a history of leukoplakia, tumors of the buccal cavity, throat,&#xD;
             and lips&#xD;
&#xD;
          -  Have difficulty swallowing (dysphagia), pain with swallowing (odynophagia), salivary&#xD;
             gland dysfunction, or xerostomia (dry mouth)&#xD;
&#xD;
          -  Are taking medications that inhibit clotting (warfarin sodium) or using prescribed&#xD;
             oral rinses (Peridex)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Clinton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Steven Clinton</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lyophilized Black Raspberry</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

